DPX-Survivac and intermittent low-dose cyclophosphamide (CPA) with or without epacadostat (E) in the treatment of subjects with advanced recurrent epithelial ovarian cancer (DeCidE1 trial): T cell responses and tumor infiltration correlate with tumor regression.

被引：2
|
作者：
Tanyi, Janos Laszlo
Dorigo, Oliver
Oza, Amit M.
Strauss, James Fredric
Pejovic, Tanja
Ghamande, Sharad A.
Ghatage, Prafull
Villella, Jeannine A.
Fiset, Stephan
MacDonald, Lisa Diana
Hrytsenko, Olga
Stanford, Marianne
Newton, Robert C.
Leopold, Lance
Rosu, Gabriela Nicola
机构：
[1] Univ Penn, Philadlephia, PA USA
[2] Stanford Canc Inst, Stanford, CA USA
[3] Princess Margaret Canc Ctr, Toronto, ON, Canada
[4] Mary Crowley Canc Res Ctr, Dallas, TX USA
[5] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[6] Augusta Univ, Georgia Canc Ctr, Augusta, GA USA
[7] Tom Baker Canc Clin, Calgary, AB, Canada
[8] Lenox Hill Hosp, New York, NY 10021 USA
[9] Immunovaccine, Quebec City, PQ, Canada
[10] Immunovaccine Inc, Halifax, NS, Canada
[11] Incyte Corp, Wilmington, DE USA
[12] Lundbeck, Vancouver, BC, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.5576
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5576
引用
收藏
页数：2
相关论文
共 4 条
  • [1] New clinical data from the DeCidE1 trial: Results on DPX-Survivac, low dose cyclophosphamide (CPA), and epacadostat (INCB024360) in subjects with advanced recurrent epithelial ovarian cancer
    Dorigo, O.
    Oza, A. M.
    Tanyi, J. L.
    Strauss, J.
    Pejovic, T.
    Ghamande, S.
    Ghatage, P.
    Villella, J.
    Fiset, S.
    MacDonald, L. D.
    Torrey, H.
    Weir, G. M.
    Hrytsenko, O.
    Stanford, M. M.
    Newton, R.
    Leopold, L.
    Rosu, G. N.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [2] Infiltration of tumor by T cells following treatment with DPX-Survivac and intermittent low dose cyclophosphamide (CPA) leads to clinical responses in advanced recurrent ovarian cancer (OvCa).
    Dorigo, Oliver
    MacDonald, Lisa Diana
    Schindler, Joanne
    Bramhecha, Yogesh
    Torrey, Heather
    Kaliaperumal, Valarmathy
    Hrytsenko, Olga
    Dirk, Brennan
    Patterson, Kelcey
    Stanford, Marianne
    Fiset, Stephan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [3] Clinical data from the DeCidE1 trial: Assessing the first combination of DPX-Survivac, low dose cyclophosphamide (CPA), and epacadostat (INCB024360) in subjects with stage IIc-IV recurrent epithelial ovarian cancer
    Dorigo, Oliver
    Tanyi, Janos Laszlo
    Strauss, James
    Oza, Amit M.
    Pejovic, Tanja
    Ghatage, Prafull
    Villella, Jeannine A.
    Fiset, Stephan
    MacDonald, Lisa Diana
    Leopold, Lance
    Rosu, Gabriela Nicola
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] Bioanalysis of samples from advanced ovarian cancer subjects treated with a combination of DPX-Survivac, metronomic cyclophosphamide, and epacadostat: Preliminary data from the phase Ib DeCidE1 Trial.
    Hrytsenko, Olga
    Weir, Genevieve
    Tram, Cynthia
    Torrey, Heather
    Newton, Robert Charles
    Stanford, Marianne
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
1